- Conditions
- Type2 Diabetes, Hyperkalemia
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
- Interventions
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Drug
- Lead sponsor
- James A. Tumlin, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Lawrenceville, Georgia • Bethlehem, Pennsylvania
- Conditions
- Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
- Interventions
- Spironolactone 25mg, Placebo
- Drug · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hyperkalemia, Resistant Hypertension
- Interventions
- Patiromer, Placebo, Spironolactone
- Drug
- Lead sponsor
- Relypsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Spironolactone, Standard care
- Drug · Other
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 38
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
- Conditions
- AML
- Interventions
- Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
- Drug · Biological
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Participants
- Interventions
- Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypertension
- Interventions
- Spironolactone, Chlorthalidone, Diet, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes, Kidney Disease, Hypertension
- Interventions
- losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hypertension
- Interventions
- amlodipine and olmesartan, losartan and HCTZ
- Drug
- Lead sponsor
- InVasc Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Tucker, Georgia
- Conditions
- Acute Myeloid Leukemia, Relapsed Adult AML
- Interventions
- Lintuzumab-Ac225, Venetoclax, Spironolactone
- Biological · Drug
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee